Advertisement

Navigating Novel Pathways and Treatment Decisions in IgA Nephropathy - Episode 10

The Future of IgAN Care: Personalized Goals and Practice-Changing Steps

Published on: 
, ,

Biomarkers beyond proteinuria and eGFR could someday match patients to the right drug. The panel defines success in individual terms and closes with practice changes, including earlier biopsy, earlier treatment, and rechecking patients thought to be stable.

Dr. Wadhwani asks Dr. Cheung how the treatment algorithm may evolve. Dr. Cheung wants better ways to identify who responds and who does not, since trials have enrolled broad populations under similar criteria. Biomarkers beyond proteinuria and eGFR would help direct therapy to patients likely to benefit. Dr. Wadhwani adds that most trials enrolled all comers, with biopsies often years old. In practice, clinicians start therapy soon after biopsy, so data in incident patients are needed. She is also eager for repeat-biopsy studies to validate biomarkers.

Dr. Geara defines success using the guideline benchmark of an eGFR slope below 1 mL/min per year, but says it must be tailored to each patient. Some patients are young and hope to start a family, so a safe window for pregnancy may be a short-term goal. The ultimate aim is to avoid dialysis and transplant. Proteinuria is the earliest marker of response, yet a 70-year-old and a 30-year-old may accept different rates of progress.

Closing the program, Dr. Wadhwani asks each panelist for one change in practice. Dr. Cheung stresses growing awareness of severity, noting that placebo patients on maximized supportive care lose roughly 4 to 5 mL/min per year. Dr. Cheung urges earlier diagnosis through referral and biopsy, early effective therapy, and combining immune-targeted agents with kidney-protective drugs. Dr. Geara encourages clinicians to revisit patients long labeled stable, since stable by past standards may be progressive disease that newer agents can stop. Dr. Wadhwani urges biopsy when hematuria is assumed to be noninflammatory, including in patients with diabetes, citing growing data that many may not have diabetic kidney disease.

Thank you for watching this HCPLive Peer Exchange series on IgA nephropathy. Please subscribe to our eNewsletter for information on upcoming video series.

Advertisement
Advertisement